STAAR Surgical (NASDAQ: STAA) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.
Valuation and Earnings
This table compares STAAR Surgical and OraSure Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|STAAR Surgical||$84.48 million||5.72||-$672,999.00||($0.11)||-106.82|
|OraSure Technologies||$135.07 million||8.92||$23.92 million||$0.54||37.52|
OraSure Technologies has higher revenue and earnings than STAAR Surgical. STAAR Surgical is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.
This table compares STAAR Surgical and OraSure Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for STAAR Surgical and OraSure Technologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
STAAR Surgical presently has a consensus target price of $12.00, suggesting a potential upside of 2.13%. OraSure Technologies has a consensus target price of $15.04, suggesting a potential downside of 25.76%. Given STAAR Surgical’s higher probable upside, equities analysts clearly believe STAAR Surgical is more favorable than OraSure Technologies.
Risk & Volatility
STAAR Surgical has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
Institutional & Insider Ownership
75.8% of STAAR Surgical shares are owned by institutional investors. Comparatively, 89.8% of OraSure Technologies shares are owned by institutional investors. 5.6% of STAAR Surgical shares are owned by company insiders. Comparatively, 7.8% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
OraSure Technologies beats STAAR Surgical on 12 of the 13 factors compared between the two stocks.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
OraSure Technologies Company Profile
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.